Open this publication in new window or tab >>Department of Chemistry for Life Sciences, Uppsala University, Uppsala, Sweden.
Department of Health Sciences, Karlstad University, Karlstad, Sweden.
Institute of Environmental Medicine, Karlinska Institutet, Stockholm, Sweden.
Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy; Human Technopole, Milan, Italy.
Department of Women’s and Children’s Health, Uppsala University, Uppsala, Sweden.
Department of Chemical, Materials and Industrial Engineering, University of Naples “Federico II”, Naples, Italy; Telethon Institute of Genetics and Medicine, Naples, Italy.
Department of Chemistry, University of Aveiro, Aveiro, Portugal.
Research Programs Unit, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Department of Environmental Medicine, Icahn School of Medicine at Mount Sinai, NY, New York, United States.
Department of Medical Sciences, Experimental Cognitive and Affective Neuroscience Lab, Uppsala University, Uppsala, Sweden.
Department of Chemistry for Life Sciences, Uppsala University, Uppsala, Sweden; Science For Life Laboratory, Uppsala University, Uppsala, Sweden.
Institute of Environmental Medicine, Karlinska Institutet, Stockholm, Sweden.
Nutrition Innovation Centre for Food and Health, Ulster University, Coleraine, United Kingdom.
Nutrition Innovation Centre for Food and Health, Ulster University, Coleraine, United Kingdom.
Department of Environmental Science, Stockholm University, Stockholm, Sweden.
Department of Neurobiology Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden.
Umeå University, Faculty of Medicine, Department of Epidemiology and Global Health. Umeå University, Faculty of Medicine, Department of Public Health and Clinical Medicine. Department of Laboratory Medicine, Lund University, Lund, Sweden.
Maternal and Child Health Division, International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR,B), Dhaka, Bangladesh.
School of Public Health, Bielefeld University, Bielefeld, Germany.
Department of Translational Research in Psychiatry, Max Planck Institute of Psychiatry, Munich, Germany.
Department of Women’s and Children’s Health, Uppsala University, Uppsala, Sweden.
Nutrition Innovation Centre for Food and Health, Ulster University, Coleraine, United Kingdom.
Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy; Human Technopole, Milan, Italy.
Department of Chemistry for Life Sciences, Uppsala University, Uppsala, Sweden.
The Department of Community and Preventive Medicine, University of Rochester, School of Medicine and Dentistry, NY, Rochester, United States.
Nutrition Innovation Centre for Food and Health, Ulster University, Coleraine, United Kingdom.
Department of Organismal Biology, Uppsala University, Uppsala, Sweden.
Department II of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany; Center for Molecular Medicine Cologne, CMMC, University of Cologne, Cologne, Germany; Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne and University Hospital Cologne, Cologne, Germany.
Show others...
2026 (English)In: Frontiers in Psychiatry, E-ISSN 1664-0640, Vol. 17, article id 1738584Article in journal (Refereed) Published
Abstract [en]
The number of people seeking help for mental illness is increasing across all ages, creating a major burden for individuals, families, and the society. While personalized medicine is advancing in other fields, diagnosis and treatment of mental disorders remain largely symptom-based and fail to capture individual, sex, and gender differences in risk, manifestation, and treatment response. Early signs of illness often go unnoticed due to the lack of monitoring tools, and stigma continues to hinder prevention and care. In some phases of life, an individual’s susceptibility to mental illness is heightened and may be influenced by changes in endocrine signalling. To address these challenges, the research project Building REsilience against MEntal illness during ENDocrine-sensitive life stages (RE-MEND) has implemented an interdisciplinary approach focusing on four critical endocrine-sensitive life stages: prenatal, puberty, peripartum, and older age. The project integrates longitudinal population-based cohorts with experimental and clinical studies to identify genetic, environmental, and endocrine factors shaping susceptibility and resilience to mental illness. Multi-omics data (genomics, epigenomics, transcriptomics, proteomics, metabolomics, lipidomics, and adductomics) will be combined with neurobiological, clinical, and behavioural measures, analysed using advanced biostatistics and machine learning. RE-MEND seeks to i) identify risk and resilience factors affecting mental health; ii) deliver biomarker panels for susceptibility, disease progression, and treatment response across sensitive life stages; iii) discover novel drug targets through repurposing strategies, and iv) promote mental health literacy and reduce stigma. The integration of biological research with communication science is anticipated to result in translatable findings, supporting earlier intervention and more effective care.
Place, publisher, year, edition, pages
Frontiers Media S.A., 2026
Keywords
endocrine-sensitive life stage, mental health, mental illness, resilience, stigma, susceptibility
National Category
Psychiatry Epidemiology Public Health, Global Health and Social Medicine
Identifiers
urn:nbn:se:umu:diva-251148 (URN)10.3389/fpsyt.2026.1738584 (DOI)001707969800001 ()41799821 (PubMedID)2-s2.0-105032105451 (Scopus ID)
2026-03-182026-03-182026-03-18Bibliographically approved